Recent Updates
Recently added Catalysts

LY3972406

Phase 2

Plaque Psoriasis | Small molecule | Immunology |Eli Lilly and Company|Last Updated: Oct 15, 2025

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindPLACEBO_CONTROLLED
Total Trials1
Total Enrollment33
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT06176768A Study of LY3972406 in Adult Participants With Moderate-to-Severe Plaque PsoriasisPHASE2 COMPLETED 33Dec 6, 2023May 6, 2025Oct 15, 202512 United States
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Percentage of Participants Achieving ≥75% Reduction From Baseline in Psoriasis Area and Severity Index (PASI-75)
Week 12

* The PASI is an investigator-administered, multi-item scale used to measure the severity of psoriasis based on lesion severity and the percent of body surface area (BSA) affected. * Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomical regions: head, trunk, upper limbs, lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). * The sum of severity scores for erythema, thickness, and scaling is multiplied by the degree of involvement for each anatomic region, and then multiplied by a constant corresponding to the region's percent BSA (0.1, 0.3, 0.2, and 0.4 for the above 4 regions, respectively). The resultant score for each anatomic region is then summed to yield the final PASI score. It ranges from 0 to 72, with higher scores reflecting greater disease severity. * The nonresponder imputation (NRI) method was used to handle missing data.

Secondary Endpoints
Change From Baseline in Percent Body Surface Area (BSA)
Baseline, Week 12
Change From Baseline in Dermatology Life Quality Index (DLQI)
Baseline, Week 12
Pharmacokinetics (PK): Observed Trough Plasma Concentration of LY3972406
Predose at Week 12
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingDOUBLE
ModelPARALLEL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
LY3972406EXPERIMENTALParticipants received an oral dose of LY3972406 for 12 weeks.
PlaceboPLACEBO_COMPARATORParticipants received an oral dose of placebo for 12 weeks.
Interventions
NameTypeDescription
LY3972406DRUGAdministered orally
PlaceboDRUGAdministered orally
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — 75 Years
SexALL
Healthy VolunteersNo
Study Sites12

Inclusion Criteria: * Have moderate-to-severe chronic plaque psoriasis for at least 6 months prior to baseline * Have venous access sufficient to allow for blood sampling * Are able to swallow oral medication Exclusion Criteria: * Have any other skin conditions, excluding plaque psoriasis * Have ...

Countries:United States
Unlock Eligibility Criteria